Loading organizations...
Loading organizations...
Shield Diagnostics is a technology company.
Shield Diagnostics provides advanced genomic diagnostic tools for the livestock industry. The company leverages proprietary microarray technology to perform genomic testing on beef and dairy cattle. These precise tests offer producers critical genetic insights, enabling informed management and treatment decisions, enhancing animal health and operational efficiency.
Founded in 2016 by Fred Turner and Sam Parlett, Shield Diagnostics emerged from recognizing the need for data-driven strategies in animal agriculture. Turner and Parlett established the company to harness genomic information, aiming to boost livestock productivity and welfare by bridging a technological gap for producers.
Primarily serving beef and dairy cattle producers, the company focuses on optimizing herd health and genetic potential. Shield Diagnostics empowers agricultural businesses with actionable intelligence, fostering superior breeding programs, effective disease management, and overall herd performance. Its long-term vision integrates genomic data into routine livestock management, advancing agricultural sustainability.
Shield Diagnostics has raised $13.0M across 1 funding round.
Shield Diagnostics has raised $13.0M in total across 1 funding round.
Shield Diagnostics is a life-sciences and biotechnology company focused on combating antimicrobial resistance (AMR) through advanced diagnostic testing. It develops tests for comprehensive antimicrobial resistance detection, enabling clinicians to select the most effective antibiotics for infections, with a vision to prevent AMR from becoming deadlier than cancer[1][4][6]. The company also explores applications in blood glucose monitoring to simplify logging and tracking for users, and provides diagnostic insights for livestock producers to inform treatment decisions[5][7]. Serving clinicians, patients, and agricultural sectors, Shield Diagnostics addresses critical gaps in infection management amid rising global AMR threats, though specific growth metrics like funding or revenue are not detailed in available data[6][7].
Shield Diagnostics, also referenced as Shield Bio in earlier announcements, emerged as a biotech player targeting the escalating crisis of antibiotic resistance. Key milestones include receiving College of American Pathology (CAP) accreditation, underscoring its commitment to high diagnostic standards[4]. A recent pivotal moment is the appointment of David Esposito to its board, bringing expertise to advance its mission[1]. While founder details and exact founding year remain undisclosed in public records, the company's evolution centers on expanding from human clinical diagnostics to potential veterinary applications, reflecting adaptability in the biotech space[6][7].
Shield Diagnostics rides the wave of precision diagnostics amid surging antimicrobial resistance, a trend projected to cause 10 million annual deaths by 2050 if unchecked. Its timing aligns with regulatory pushes for better stewardship and post-pandemic emphasis on rapid infection diagnostics. Market forces like increasing superbug prevalence and demand for targeted therapies favor its tests, influencing the ecosystem by enabling data-driven prescribing in hospitals and agriculture, potentially curbing resistance spread[1][4][6].
Next steps likely include scaling diagnostic platforms, leveraging board expertise like David Esposito's for partnerships, and expanding into integrated health tech for real-time monitoring. Trends like AI-enhanced resistance prediction and global AMR initiatives will shape its path, evolving its influence from niche tester to key ecosystem enabler in lifesaving biotech. This positions Shield Diagnostics to fortify defenses against a silent pandemic, echoing its core vision from the outset[1][6].
Shield Diagnostics has raised $13.0M in total across 1 funding round.
Shield Diagnostics's investors include Tectonic Capital.
Shield Diagnostics has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Series A in June 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2018 | $13.0M Series A | Tectonic Capital |